Agomelatine in the treatment of major depressive disorder: An assessment of benefits and risks

Current Neuropharmacology

Volumn 12, Issue 5, 2014, Pages 387-398

  Gahr, Maximilian ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Adverse drug reaction; Antidepressant; Hepatopathy; Liver enzymes; Melatonin; Pharmacovigilance; S20098

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; AGOMELATINE; AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CIPROFLOXACIN; CYTOCHROME P450; DULOXETINE; ENOXACIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GREPAFLOXACIN; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PAROXETINE; PLACEBO; PROPRANOLOL; RIFAMPICIN; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ABDOMINAL PAIN; ARTICLE; BACKACHE; BLURRED VISION; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FATIGUE; GENETIC POLYMORPHISM; HEADACHE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FAILURE; LIVER TOXICITY; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MIGRAINE; NAUSEA; NEUROMODULATION; NEUROTRANSMISSION; PARESTHESIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLICATION; RELAPSE; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINUSITIS; SKIN DISEASE; SLEEP WAKING CYCLE; SOMNOLENCE; TREMOR; XEROSTOMIA;

EID: 84924105867     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12999140619122914     Document Type: Article

References (89)

1. EMA. Valdoxan (Agomelatine). 2008. Summary of product characteristics (last updated: 10/12/2013). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/000915/WC500046227.pdf [Accessed May 11th 2014].
2. Kennedy, S.; Eisfeld, B. Agomelatine and its therapeutic potential in the depressed patient. Neuropsych. Dis. Treat., 2007, 3, 423-428. PMC2655086
3. Lerner, A.; Case, J.; Takahashi, Y.; Lee, T.; Mori, W. Isolation of melatonin, the pineal factor that lightens melanocytes. J. Am. Chem. Soc., 1958, 80, 2587. DOI: http://dx.doi.org/10.1021/ ja01543a060
4. Nordlund, J.; Lerner, A. The effects of oral melatonin on skin color and on the release of pituitary hormones. J. Clin. Endocrinol. Metabol., 1977, 45, 768-774. DOI: http://dx.doi.org/10.1210/jcem- 45-4-768
5. Brzezinski, A.; Vangel, M.; Wurtman, R.; Norrie, G.; Zhdanova, I.; Ben-Shushan, A.; Ford, I. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep. Med. Rev., 2005, 9, 41-50.
6. Popoli, M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs, 2009, 23 (Suppl. 2), 27-34. doi: 10.2165/ 11318640-000000000-00000.
7. Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. Antidepressant efficacy of agomelatin: meta-analysis of published and unpublished studies. BMJ, 2014, 348, g1888. http://dx.doi.org/10.1136/bmj.g1888
8. Howland, R. Publication bias and outcome reporting bias: agomelatine as a case example. J. Psychosoc. Nurs. Ment. Health. Serv., 2011, 49, 11-14. DOI: http://dx.doi.org/10.3928/02793695- 20110809-01
9. Kennedy, S.; Rizvi, S. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs, 2010, 24, 479-499. DOI: http://dx.doi.org/10.2165/ 11534420-000000000-00000
10. de Bodinat, C.; Guardiola-Lemaitre, B.; Mocaer, E.; Renard, P.; Munoz, C.; Millan, M. Agomelatine, the first melatonergic antidepressant. discovery, characterization and development. Nat. Rev. Drug Discov., 2010, 9, 628-42. CrossRef DOI: http://dx.doi. org/10.1017/S1461145713000679
11. Lam, R. The importance of early symptom relief in antidepressant treatment: focus on agomelatine. J. Psychopharmacol., 2010, 24, 27-30. DOI: http://dx.doi.org/10.1177/1359786810372979
12. Llorca, P. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. J. Psychopharmacol., 2010, 24, 24(21-6). DOI: http://dx.doi.org/10.1177/ 1359786810372978
13. Hickie, I.; Rogers, N. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet, 2011, 378, 621-631. DOI: http://dx.doi.org/10.1016/S0140-6736(11)60095-0
14. San, L.; Arranz, B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry, 2008, 23, 396-402. CrossRef DOI: http://dx.doi.org/10.1016/j.eurpsy.2008.04.002
15. Demyttenaere, K. Agomelatine: a narrative review. Eur. Neuropsychopharmacol., 2011, 21 Suppl 4, S703-709. DOI: http://dx.doi. org/10.1016/j.euroneuro.2011.07.004
16. Koesters, M.; Guaiana, G.; Cipriani, A.; Becker, T.; Barbui, C. Agomelatine efficacy and accetability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br. J. Psychiatry, 2013, 203, 179-187.
17. Guaiana, G.; Gupta, S.; Chiodo, D.; Davies, S.; Haederle, K.; Koesters, M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst. Rev., 2013, 12, CD008851. PubMed ID: 24343836
18. Gahr, M.; Freudenmann, R.; Connemann, B.; Hiemke, C.; Schonfeldt-Lecuona, C. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry, 2013, 56, 214-220. rossRef DOI: http://dx.doi.org/10.1055/s-0033-1353156
19. Montastruc, F.; Scotto, S.; Vaz, I.; Guerra, L.; Escudero, A.; Sainz, M.; Falomir, T.; Bagheri, H.; Herdeiro, m.; Venegoni, M.; Montastruc, J.; Carvajal, A. Hepatotoxicity Related to Agomelatine and Other New Antidepressants: A Case/Noncase Approach With Information From the Portuguese, French, Spanish, and Italian Pharmacovigilance Systems. J. Clin. Psychopharmacol., 2014, 34, 327-330. doi: 10.1097/JCP.0000000000000094.
20. Calandre, E.; Slim, M.; Garcia-Leiva, J.; Rodriguez-Lopez, C.; Torres, P.; Rico-Villademoros, F. Agomelatine for the Treatment of Patients with Fibromyalgia and Depressive Symptomatology: An Uncontrolled, 12-Week, Pilot-Study. Pharmacopsychiatry, 2014, 47, 67-72. doi: 10.1055/s-0033-1363659
21. Pardini, M.; Cordano, C.; Benassi, F.; Mattei, C.; Sassos, D.; Guida, S.; Serrati, C.; Primavera, A.; Amore, M.; Cocito, L.; Emberti, G. L. Agomelatine but not melatonin improves fatigue perception: A longitudinal proof-of-concept study. Eur. Neuropsychopharmacol., 2014, 24, 939-944.
22. Calabrese, J.; Guelfi, J.; Perdrizet-Chevallier, C.; Group, A.B.S. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord., 2007, 9, 628-635. CrossRef DOI: http://dx.doi.org/10.1111/j.1399-5618.2007.00507.x
23. Stein, D.; Ahokas, A.; Albarran, C.; Olivier, V.C. A. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontiunation study. J. Clin. Psychiatry, 2012, 73, 1002-1008.
24. Levitan, M.; Papelbaum, M.; Nardi, A. A review of preliminary observations on agomelatine in the tratment of anxiety disorders. Exp. Clin. Psychopharmacol., 2012, 20, 504-509. CrossRef DOI: http://dx.doi.org/10.1037/a0030263
25. Fornaro, M.; Prestia, D.; Colicchio, S.; Perugi, G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr. Neuropsychopharmacol., 2010, 8, 287-304. DOI: http://dx.doi.org/10.2174/157015910792246227
26. San, L.; Arranz, B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry, 2008, 23, 396-402. CrossRef DOI: http:// dx.doi.org/10.1016/j.eurpsy.2008.04.002
27. Smeraldi, E.; Delmonte, D. Agomelatine in depression. Expert. Opin. Drug. Saf., 2013, 12, 873-880. CrossRef DOI: http://dx.doi. org/10.1517/14740338.2013.828690
28. Zlotos, D. Recent advantages in melatonin receptor ligands. Arch. Pharm. Chem. Life. Sci., 2005, 338, 229-247. CrossRef DOI: http:// dx.doi.org/10.1002/ardp.200400996
29. Masson-Pevet, M.; Recio, J.; Guerrero, H.; Mocaer, E.; Delagrange, P.; Guardiola-Lemaitre, B.; Pevet, P. Effects of two melatonin analogues, s-20098 and s-20928, on melatonin receptors in the pars tuberalis of the rat. J. Pin. Res., 1998, 25, 172-176. DOI: http://dx. doi.org/10.1111/j.1600-079X.1998.tb00556.x
30. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amosse, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.; Malpaux, B.; Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delegrange, P.; Boutin, J. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn. Schmiedebergs. Arch. Pharmacol., 2003, 367, 553-561. CrossRef DOI: http://dx.doi.org/10.1007/s00210-003-0751-2
31. Dubocovich, M.; Rivierea-Bermudez, M.; Gerdin, M.; Masana, M. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci., 2003, 8, d1093-1098. PubMed ID: 12957828
32. Wu, Y.; Zhou, J.; Balesar, R.; Unmehopa, U.; Bao, A.; Jockers, R.; Van Heerikhuize, J.; Swaab, D. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colcalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J. Comp. Neurol., 2006, 499, 897-910. CrossRef DOI: http://dx.doi.org/10.1002/cne.21152
33. Alarma-Estrany, P.; Pintor, J. Melatonin receptors in the eye: locaton, second messengers and role in ocular physiology. Pharmacol. Ther., 2007, 113, 507-522. DOI: http://dx.doi.org/ 10.1016/j.pharmthera.2006.11.003
34. Pompili, M.; Serafini, G.; Innamorati, M.; Venturini, P.; Fusar-Poli, P.; Sher, L.; Amore, M.; Girardi, P. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J. Biol. Psychiatry, 2013, 14, 412-431. DOI: http://dx.doi.org/10.3109/15622975.2013.765593
35. Wehr, T. Photoperiodism in humans and other primates: Evidence and implications. J Biol. Rhythms, 2001, 16, 348-364. DOI: http:// dx.doi.org/10.1177/074873001129002060
36. Howland, R. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf., 2011, 34, 709-731. DOI: http://dx.doi.org/10.2165/11593960-000000000-00000
37. Millan, M.; Marin, P.; Kamal, M.; Jockers, R.; Chanrion, B.; Labasque, M.; Bockaert, J.; Mannoury la Cour, C. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors. Int. J. Neuropsychopharmacol., 2010, 14, 768-783. CrossRef DOI: http://dx.doi.org/ 10.1017/S1461145710001045
38. Millan, M.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman- Tancredi, A.; Pasteau, V.; Rivet, J.; Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5- hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmaco.l Exp. Ther., 2003, 306, 954-964. CrossRef DOI: http:// dx.doi.org/10.1124/jpet.103.051797
39. Rosen, R.; Lane, R.; Menza, M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol., 1999, 19, 67-85. DOI: http://dx.doi.org/10.1097/00004714-199902000-00013
40. Landolt, H.; Meier, V.; Burgess, H.; Finelli, L.; Cattelini, F.; Achermann, P.; Borbely, A. Serotonin-2-receptors and human sleep: effects of a selective antagonist on EEG power spectra. Neuropsychopharmacology, 1999, 21, 455-466. CrossRef DOI: http://dx.doi.org/10.1016/S0893-133X(99)00052-4
41. Landolt, H.; Wehrle, R. Antagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition, and mood? Eur. J. Neurosci., 2009, 29, 1795-1809. DOI: http://dx.doi.org/ 10.1111/j.1460-9568.2009.06718.x
42. Stahl, S. Novel mechanisms of antidepressant action: norepinehprine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int. J. Neuropsychopharmacol., 2007, 10, 575-578. PMID: 17681087
43. EMEA. CHMP assessment report for valdoxan. 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf [Accessed May 5th 2014].
44. Kasper, S.; Hamon, M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J. Biol. Psychiatry, 2009, 10, 117-126. CrossRef DOI: http://dx.doi.org/10.1080/15622970902717024
45. Eser, D.; Baghai, T.; Moller, H. Evidence of agomelatinés antidepressant efficacy: the key points. Int. Clin. Psychopharmacol., 2007, 22(Suppl 2), DOI: http://dx.doi.org/10.1097/01.yic.0000277958. 83475.d5
46. Millan, M.; Brocco, M.; Gobert, A.; Dekeyne, A. Anxiolytic properties of agomelatine, an antidepressant with melatonergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl.), 2005, 177, 448-458. DOI: http://dx. doi.org/10.1007/s00213-004-1962-z
47. Wagner, J.; Wagner, M.; Hening, W. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insonmnia. Ann. Pharmacother., 1998, 32, 680-691. CrossRef DOI: http://dx. doi.org/10.1345/aph.17111
48. Kalsbeck, A.; La Fleur, S.; Van Heijningen, C.; Buijs, R. Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver. J. Neurosci., 2004, 24, 7604-7613. DOI: http://dx.doi.org/10.1523/JNEUROSCI.5328-03.2004
49. 2Breceptor profile in the rat central nervous system. Neuroscience, 1997, 76, 323-329. CrossRef DOI: http://dx.doi.org/10.1016/ S0306-4522(96)00480-0
50. Hanoun, N.; Mocaer, E.; Boyer, P.; Hamon, M.; Lanfumey, L. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology, 2004, 47, 515-526. CrossRef DOI: http://dx. doi.org/10.1016/j.neuropharm.2004.06.003
51. Singh, S.; Singh, V.; Nilamadhab, K. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int. J. Neuropsychopharmacol., 2012, 15, 417-428. CrossRef DOI: http:// dx.doi.org/10.1017/S1461145711001301
52. Soumier, A.; Banasr, M.; Lortet, S.; Masmejean, F.; Bernard, N.; Kerkerian-Le-Goff, L.; Gabriel, C.; Millan, M.; Mocaer, E.; Daszuta, A. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology, 2009, 34, 2390-2403. DOI: http://dx.doi.org/10.1038/npp.2009.72
53. Molteni, R.; Calabrese, F.; Pisoni, S.; Gabriel, C.; Mocaer, E.; Racagni, G.; Riva, M. Synergistic mechanisms in the modulation of the neurotrophic BDNF in the rat prefrontal cortex following acute agomelatine administration. World J. Biol. Psychiatry, 2010, 11, 148-153. CrossRef DOI: http://dx.doi.org/10.3109/ 15622970903447659
54. Racagni, G.; Riva, M.; Molteni, R.; Musazzi, L.; Calabrese, F.; Popoli, M.; Tardito, D. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J. Biol. Psychiatry, 2011, 12, 574-587. DOI: http://dx.doi.org/10.3109/ 15622975.2011.595823
55. Tardito, D.; Milanese, M.; Bonifacino, T.; Musazzi, L.; Grilli, M.; Mallei, A.; Mocaer, E.; Gabriel-Garcia, C.; Racagni, G.; Popoli, M.; Bonanno, G. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci., 2010, 11, CrossRef DOI: http://dx.doi. org/10.1186/1471-2202-11-68
56. Skene, D.; Arendt, J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann. Clin. Biochem., 2006, 43, 344-53. DOI: http://dx.doi.org/10.1258/ 000456306778520142
57. Van Reeth, O.; Weibel, L.; Olivares, E.; Maccari, S.; Mocaer, E.; Turek, F. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 280, R1582-1591. PMID: 11294784
58. Redman, J.; Francis, A. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol. Rhythms, 1998, 13, 39-51. CrossRef DOI: http://dx.doi.org/10.1177/074873098128999907
59. Leproult, R.; Van Onderbergen, A.; Lhermite-Baleriaux, M.; Van Cauter, E.; Copinschi, G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. (Oxf.), 2005, 63, 298-304.
60. Racagni, G.; Riva, M.; Popoli, M. The interaction between the internal clock and antidepressant efficacy. Int. Clin. Psychopharmacol., 2007, 22 Suppl 2 DOI: http://dx.doi.org/10.1097/01.yic.0000277957. 75852.c7
61. Descamps, A.; Rousset, C.; Millan, M.; Spedding, M.; Delagrange, P.; Cespuglio, R. Influence of the novel antidepressant and melatonin agonist/serotonergic2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology (Berl.), 2009, 205, 93-106. CrossRef DOI: http://dx.doi.org/ 10.1007/s00213-009-1519-2
62. DeBerardis, D.; Di Iorio, G.; Acciavatti, T.; Conti, C.; Serroni, N.; Olivierei, L.; Cavuto, M; Martinotti, G.; Janiri, L.; Moschetta, F.; Conti, P.; Di Giannantonio, M. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol. Dis. Drug. Targ., 2011, 10, 119-132. CrossRef DOI: http://dx.doi.org/10.2174/187152711794488674
63. Kennedy, S.; Rivzi, S.; Fulton, K.; Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol., 2008, 28, 329-333. DOI: http://dx.doi.org/ 10.1097/JCP.0b013e318172b48c
64. Montgomery, S.; Kennedy, S.; Burrows, G.; Lejoyeux, M.; Hindmarch, I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol., 2004, 19, 271-280. DOI: http:// dx.doi.org/10.1097/01.yic.0000137184.64610.c8
65. 2receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Psychopharmacol., 2007, 10, 661-673. PMID: 17477888
66. Loo, H.; Hale, A.; D'Haenen, H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol., 2002, 17, 239-247. CrossRef DOI: http://dx.doi.org/10.1097/ 00004850-200209000-00004
67. Kennedy, S.; Emsley, R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 2006, 16, 223-244. DOI: http://dx.doi.org/10.1016/ j.euroneuro.2005.09.002
68. Loo, H.; Dalery, J.; Macher, J.; Payen, A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninagonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale, 2003, 29, 165-171.
69. Stuhec, M. Agomelatine-induced hepatotoxicity. Wien. Klin. Wochenschrf., 2013, 125, 225-226. CrossRef DOI: http://dx.doi. org/10.1007/s00508-013-0344-0
70. Gruz, F.; Raffa, S.; Santucci, C.; Papale, R.; Videla, M.; Fernandez, M.; Yantorno, S.; Descalzi, V. Agomelatine: fulminant liver failure in a patient with fatty liver. Gastroenterol. Hepatol., 2014, 37, 92- 94. DOI: http://dx.doi.org/10.1016/j.gastrohep.2013.04.008
71. Voican, C.; Corruble, E.; Naveau, S.; Perlemuter, G. Antidepressantinduced liver injury: a review for clinicians. Am. J. Psychiatry, 2014, 171, 404-415. doi:10.1176/appi.ajp.2013.13050709
72. EMA. Post authorisation opinion regarding Agomelatine. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/Summary_of_opinion/human/000916/WC500150138.pdf [Accessed May 7th 2014].
73. Lemoine, P.; Guilleminault, C.; Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry, 2007, 68, 1723-1732. DOI: http://dx.doi.org/10.4088/JCP.v68n1112
74. Stahl, S.; Fava, M.; Trivedi, M.; Caputo, A.; Shah, A.; Post, A. Agomelatine in the treatment of major depressive disorder: an 8- week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry, 2010, 71, 616-626. DOI: http://dx.doi.org/10.4088/ JCP.09m05471blu
75. Zajecka, J.; Schatzberg, A.; Stahl, S.; Shah, A.; Caputo, A.; Post, A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled trial. J. Clin. Psychopharmacol., 2010, 30, 135-144.
76. Hale, A.; Corral, R.-M.; Menacci, C.; Ruiz, J.; Severo, C.; Gentil, V. Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: a randomized, double-blind study. Int. Clin. Psychopharmacol., 2010, 25, 305-314. DOI: http:// dx.doi.org/10.1097/YIC.0b013e32833a86aa
77. Goodwin, G.; Emsley, R.; Rembry, S.; Rouillon, F.; Group, A.S. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24- week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 2009, 70, 1128-1137. CrossRef DOI: http://dx.doi.org/ 10.1016/j.gastrohep.2013.04.008
78. Kasper, S.; Hajak, G.; Wulff, K.; Hoogendijk, W.; Montejo, A.; Smeraldi, E.; Rybakowski, J.; Quera-Salva, M.; Wirz-Justice, A.; Picarel-Blanchot, F.; Bayle, F. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry, 2010, 71, 109-120. CrossRef DOI: http://dx.doi.org/ 10.4088/JCP.09m05347blu
79. Quera-Salva, M.; Hajak, G.; Philip, P.; Montplaisir, J.; Keufer-Le Gall, S.; Laredo, J.; Guilleminault, C. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int. Clin. Psychopharmacol., 2011, 26, 252-262. CrossRef DOI: http://dx.doi.org/ 10.1097/YIC.0b013e328349b117
80. Heun, R.; Ahokas, A.; Boyer, P.; Gimenez-Montesinos, N.; Pontes- Soares, F.; Olivier, V.; Group, A.S. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J. Clin. Psychiatry, 2013, 74, 587-594. CrossRef DOI: http://dx.doi.org/10.4088/JCP.12m08250
81. Martinotti, G.; Sepede, G.; Gambi, F.; Di Iorio, G.; De Berardis, D.; Di Nicola, M.; Onofrj, M.; Janiri, L.; Di Giannantonio, M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J. Clin. Psychopharmacol., 2012, 32, 487-491. CrossRef DOI: http://dx.doi.org/ 10.1097/JCP.0b013e31825d6c25
82. EMEA. Questions and answers on recommendation for refusal of marketing authorisation for Valdoxan/Thymanax. 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_ QA/2009/12/WC500017305.pdf [Accessed May 3th 2014].
83. Montgomery, S.; Moller, H. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int. Clin. Psychopharmacol., 2009, 24, 111-118. CrossRef DOI: http://dx.doi.org/10.1097/YIC.0b013e32832a8eb2
84. Melander, H.; Salmonson, T.; Abadie, E.; van Zwieten-Boot, B. A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur. Neuropsychopharmacol., 2008, 18, 623-627. CrossRef DOI: http:// dx.doi.org/10.1016/j.euroneuro.2008.06.003
85. Turner, E.; Matthews, A.; Linardatos, E.; Tell, R.; Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med., 2008, 358, 252-260. CrossRef DOI: http://dx.doi.org/10.1056/NEJMsa065779
86. Cipriani, A.; Furukawa, T.; Salanti, G.; Geddes, J.; Higgins, J.; Churchill, R.; Watanabe, N.; Nakagawa, A.; Omori, I.; McGuire, H.; Tansella, M.; Barbui, C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet, 2009, 373, 746-758. CrossRef DOI: http://dx.doi. org/10.1016/S0140-6736(09)60046-5
87. Goodwin, G.; Boyer, P.; Emsley, R.; Rouillon, F.; de Bodinat, C. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Int. Clin. Psychopharmacol., 2013, 1, 20-28. DOI: 10.1097/YIC.0b013e32835b0814
88. Corruble, E.; de Bodinat, C.; Belaidi, C.; Goodwin, G.; agomelatine study group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int. J. Neuropsychopharmacol., 2013, 16, 2219- 2234.
89. Frobose, T.; Slawik, H.; Schreiner, R.; Vesely, Z.; Wiegand, M.; Bauml, J.; Forstl, H. Agomelatine improves sleep in a patient with fatal familial insomnia. Pharmacopsychiatry, 2012, 45, 34-36. CrossRef DOI: http://dx.doi.org/10.1055/s-0031-1287778